Physician profile
Scott Russell
NPI 1174025795
$5,788.25
in general payments reported to CMS, 2019-2025
21 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $41.76 · 2022: $1,072 · 2023: $1,635 · 2024: $1,598 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,057.80 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,005.89 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $964.52 | 2022-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $643.82 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.79 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $410.98 | 2022-2025 | Wegovy, Ozempic |
| Phathom Pharmaceuticals, INC. | $154.33 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $149.37 | 2023 | |
| Abbott Laboratories | $136.38 | 2024 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.97 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $114.80 | 2023-2025 | Rexulti |
| Edwards Lifesciences Corporation | $94.86 | 2024 | |
| Boston Scientific Corporation | $91.91 | 2024 | |
| Pfizer INC. | $70.06 | 2020-2025 | |
| Exact Sciences Corporation | $68.72 | 2023-2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $52.59 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $21.55 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $16.06 | 2023 | |
| Amneal Pharmaceuticals LLC | $15.35 | 2023 | Lyvispah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2023 | Relistor |
| E.R. Squibb & Sons, L.L.C. | $14.03 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.